Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study

Table 2 Parasitological efficacy of SP among women enrolled in Burkina-Faso and Mali

Characteristics	Burkina-Faso		Mali		All
Characteristics	N=312		N =268		N =580
PCR Days	Non- adjusted	Adjusted	Non- adjusted	Adjusted	Non- adjusted	Adjusted
Day 7:
Number at risk	307	307	265	265	572	572
Failures, n (%)
ETF	0	0	0	0	0	0
LCF	0	0	0	0	0	0
LPF	2 (0.5)	1 (0.3)	1 (0.4)	1 (0.4)	3 (0.5)	2 (0.3)
ACPR n (%)	305 (99.5)	306 (99.7	264 (99.6)	264 (99.6)	569 (99.5)	570 (99.7)
Day 14:
Number at risk	306	306	260	260	566	566
Failures n (%)
ETF	0	0	0	0	0	0
LCF	0	0	0	0	0	0
LPF	3 (1.0)	2 (0.7)	1 (0.4)	1 (0.4)	4 (0.7)	3 (0.5)
ACPR n (%)	303 (99.0)	304 (99.3	259 (99.6)	259 (99.6	562 (99.3)	563 (99.5)
Day 21:
Number at risk	300	300	259	259	559	559
Failures n (%)
ETF	0	0	0	0	0	0
LCF	0	0	0	0	0	0
LPF	3 (1.0)	2 (0.7)	1 (0.4)	1 (0.4)	4 (0.7)	3 (0.5)
ACPR n (%)	297 (99.0)	298 (99.3)	258 (99.6)	258 (99.6)	542 (99.5)	556 (99.5)
Day 28:
Number at risk	297	297	259	259	556	556
Failures n (%)
ETF	0	0	0	0	0	0
LCF	0	0	0	0	0	0
LPF	7 (2.4)	3 (1.0)	2 (0.8)	2 (0.8)	9 (1.6)	5 (0.9)
ACPR n (%)	290 (97.6)	294 (99.0)	257 (99.2)	257 (99.2)	547 (98.4)	551 (99.1)
Day 35:
Number at risk	295	294^a	253	254	548	547^a
Failures n (%)
ETF	0	0	0	0	0	0
LCF	0	0	0	0	0
LPF	14 (4.8)	4 (1.4)	2 (0.8)	2 (0.8)	16 (2.9)	6 (1.1)
ACPR n (%)	281 (95.2)	290 (98.6)	251 (99.2)	252 (99.2)	532 (97.1)	541 (98.9)
Day 42:
Number at risk	293	292^a	253	251^a,b	546	544^c
Failures n (%)
ETF	0	0	0	0	0	0
LCF	0	0	0	0	0	0
LPF	19 (6.5)	4 (1.4)	8 (3.2)	2 (0.8)	27 (4.9)	6 (1.1)
ACPR n (%)	274 (93.5)	288 (98.6)	245 (96.8)	249 (99.2)	519 (95.1)	538 (98.9)
Median (range) time in days	35 (7–43)^d	21 (7–35)^e	42 (7–42)^d	18 (7–29)^e	35 (7–43)^d	21 (7–35)^e

Notes: PCR, Polymerase Chain Reaction; ETF, Early Treatment Failure; LCF, Late Treatment Failure; LPF, Late parasitological Failure; ACPR, Adequate Clinical and Parasitological Response.
^aOne PCR inconclusive.
^bPCR analysis not conducted for 1 woman with recurrent parasitaemia in Mali.
^cPCR inconclusive (1 from Mali, 1 from Burkina) and no PCR analysis available (1 from Mali). These three cases were censored in the survival analysis.
^dMedian (range) time to reinfection.
^eMedian (range) time to PCR-adjusted failure.

ISSN: 1475-2875